YUM BRANDS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that YUM BRANDS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.21B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $7.55B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $7.08B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $6.84B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $6.58B | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $1.74B | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | $1.45B | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | $1.20B | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | $1.26B | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | $1.69B | Feb 22, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.49B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $1.60B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $1.33B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.58B | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $332.00M | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | $283.00M | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | $206.00M | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | $83.00M | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | $488.00M | Feb 22, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.57B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.40B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $2.32B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $2.19B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $2.14B | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $482.00M | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | $471.00M | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | $300.00M | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | $250.00M | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | $546.00M | Feb 22, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 26, 2015 | $28.00M | Feb 16, 2016 |
| FY2015 | Dec 27, 2014 | $30.00M | Feb 16, 2016 |
| FY2015 | Dec 28, 2013 | $31.00M | Feb 16, 2016 |
| FY2014 | Dec 29, 2012 | $30.00M | Feb 17, 2015 |
| FY2013 | Dec 31, 2011 | $34.00M | Feb 18, 2014 |
| FY2012 | Dec 25, 2010 | $33.00M | Feb 20, 2013 |
| FY2011 | Dec 26, 2009 | $31.00M | Feb 21, 2012 |
| FY2010 | Dec 27, 2008 | $34.00M | Feb 15, 2011 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.01B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.69B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $1.60B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $1.43B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.71B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $1.31B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $1.32B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $1.18B | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $1.03B | Feb 20, 2020 |
| FY2015 | Dec 26, 2015 | $2.14B | Feb 16, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $371.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $257.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $285.00M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $279.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $230.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $160.00M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $196.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $234.00M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $318.00M | Feb 20, 2020 |
| FY2015 | Dec 26, 2015 | $973.00M | Feb 16, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.20B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $6.73B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $6.23B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $5.85B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $5.97B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $5.85B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $5.23B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $4.13B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $5.31B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $5.45B | Feb 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.52B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $14.38B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $14.09B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $14.72B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $14.34B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $13.74B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $13.25B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $12.06B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $11.65B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $11.07B | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | ($7.93B) | Feb 21, 2019 |
| FY2015 | Dec 26, 2015 | $911.00M | Feb 16, 2016 |
| FY2015 | Dec 27, 2014 | $1.55B | Feb 16, 2016 |
| FY2014 | Dec 28, 2013 | $2.17B | Feb 17, 2015 |
| FY2013 | Dec 29, 2012 | $2.15B | Feb 18, 2014 |
| FY2012 | Dec 31, 2011 | $1.82B | Feb 20, 2013 |
| FY2011 | Dec 25, 2010 | $1.58B | Feb 21, 2012 |
| FY2010 | Dec 26, 2009 | $1.03B | Feb 15, 2011 |
| FY2009 | Dec 27, 2008 | ($108.00M) | Feb 17, 2010 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $969.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $736.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $642.00M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $638.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $657.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $597.00M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $530.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $525.00M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $512.00M | Feb 20, 2020 |
| FY2015 | Dec 26, 2015 | $656.00M | Feb 16, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.01B) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($7.26B) | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | ($7.62B) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($8.51B) | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | ($8.05B) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($7.48B) | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | ($7.63B) | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | ($7.59B) | Feb 20, 2020 |
| FY2015 | Dec 26, 2015 | $1.15B | Feb 16, 2016 |
| FY2015 | Dec 27, 2014 | $1.74B | Feb 16, 2016 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $709.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $616.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $512.00M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $367.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $486.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $730.00M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $605.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $292.00M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $1.52B | Feb 20, 2020 |
| FY2015 | Dec 26, 2015 | $737.00M | Feb 16, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 26, 2015 | $3.80B | Feb 16, 2016 |
| FY2014 | Dec 27, 2014 | $3.20B | Feb 17, 2015 |
| FY2013 | Dec 28, 2013 | $2.80B | Feb 18, 2014 |
| FY2012 | Dec 29, 2012 | $2.80B | Feb 20, 2013 |
| FY2011 | Dec 31, 2011 | $3.00B | Feb 21, 2012 |
| FY2010 | Dec 25, 2010 | $3.56B | Feb 15, 2011 |
| FY2010 | Dec 26, 2009 | $3.23B | Feb 15, 2011 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 5 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 22, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 5 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 22, 2021 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $789.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $752.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $678.00M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $649.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $592.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $566.00M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $511.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $462.00M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $416.00M | Feb 20, 2020 |
| FY2015 | Dec 26, 2015 | $730.00M | Feb 16, 2016 |